Figure 4.

Kaplan‐Meier curves of the 3 biomarkers at the end of radiotherapy for distant metastasis‐free survival (DMFS) and overall survival (OS) in nasopharyngeal carcinoma patients. A, DMFS of patients with detectable or undetectable Epstein‐Barr virus (EBV) DNA at the end of radiotherapy. B, DMFS of patients with detectable or undetectable BamHI A rightward transcripts encoded microRNA (miR‐BART7)‐3p at end of radiotherapy. C, DMFS of patients with detectable or undetectable miR‐BART13‐3p at end of radiotherapy. D, DMFS of patients in 4 subgroups based on the combination of EBV DNA and miR‐BART7‐3p at end of radiotherapy. Color coding is explained at the bottom of the panel. E, DMFS of patients at different risk of poor DMFS based on the combination of EBV DNA and miR‐BART7‐3p at end of radiotherapy. Low, intermediate, and high risk was defined as undetectable EBV DNA and miR‐BART7‐3p, detectable EBV DNA or miR‐BART7‐3p, and detectable EBV DNA and miR‐BART7‐3p, respectively. F, OS of patients at different risk of poor OS based on the combination of EBV DNA and miR‐BART7‐3p at end of radiotherapy